An investigational oral selective orexin receptor 2 agonist significantly improved measures of wakefulness, sleepiness, and ...

Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

Focusing magnetic resonance-guided focused ultrasound thalamotomy on a newly identified target in the brain could improve ...

With set clinic hours, round-the-clock availability, and a 3-month rotation schedule, life as a cruise ship doctor offers a ...

In both children and adults, the drug allows for decreasing glucocorticoid dosing to physiological levels while still ...

Surveillance endoscopy conducted every 2 years for Barrett’s esophagus offers no benefit in overall survival compared with ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

Just 25 years ago, venous thromboembolism treatment regimens were primitive, writes Dr Holley. But two trials showed that apixaban and rivaroxaban are proving excellent options for tackling VTE.

In this interview, Dr Ryan Stidham discusses the various ways in which artificial intelligence is being used to streamline ...

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...

The median age at symptom onset in the cohort was 55 years, ranging from 16 to 81 years. Data from patients’ initial ...

The US Food and Drug Administration (FDA) has approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 ...